Nexavar Significantly Extends Survival of Liver Cancer Patients
CHICAGO, Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc. today announced that Nexavar(R) (sorafenib) tablets significantly extended overall survival in patients with hepatocellular carcinoma (HCC), or primary liver cancer versus those taking placebo by 44%. Results were presented at the 43rd annual meeting of the American Society of Clinical Oncology (ASCO). Th...Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
Bayer HealthCare Pharmaceuticals Inc. (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Supplemental New Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. Nexavar is currently...Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
- First Agent Ever to Demonstrate Significant Survival Benefit inLiver Cancer - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- BayerHealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc.today announced that Nexavar(R) (sorafenib) tablets significantlyextended overall survival in patients with hepatocellular carcinoma(HCC), or primary liver cancer versus those taking placebo by 4...Review of Nexavar Data Presented at ASCO 2007- Investor Conference Call on June 4, 2007
Leverkusen, Germany, May 31, 2007- Results from variousclinical studies including a pivotal Phase III trial in patientswith advanced hepatocellular carcinoma, or primary liver cancerwith Nexavar (sorafenib) tablets will be presented at the AnnualMeeting of the American Society of Clinical Oncology (ASCO) inChicago, USA from June 1 - 5, 2007. On this occasion a conference call for i...